By Dr Subotheni Thavaneswaran

Journal articles

Thavaneswaran S; Lin F; Grady JP; Espinoza D; Huang ML; Chinchen S; Sebastian L; Kansara M; Mersiades T; Lee CK; Desai J; Grimison P; Brown M; Millward M; Harrup R; O’Byrne K; Nagrial A; Craft P; Simes J; Joshua AM; Thomas DM, 2024, 'A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation', npj Precision Oncology, 8, http://dx.doi.org/10.1038/s41698-024-00698-4

Deng F; Li Y; Yang B; Sang R; Deng W; Kansara M; Lin F; Thavaneswaran S; Thomas DM; Goldys EM, 2024, 'Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing', Nature Communications, 15, pp. 1818, http://dx.doi.org/10.1038/s41467-024-46001-8

Lin FP-Y; Grady JP; Napier CE; Callow M; Thavaneswaran S; Huang ML; Zaheed M; Kansara M; Sebastian L; Ballinger ML; Simes J; Thomas DM, 2024, 'Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board.', Journal of Clinical Oncology, 42, pp. 1557 - 1557, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.1557

Novis E; Glover A; Grady JP; Silvestri A; Thavaneswaran S; Lin F; Ballinger ML; Thomas DM, 2024, 'Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program', Surgery (United States), http://dx.doi.org/10.1016/j.surg.2024.05.058

Lin FP; Mersiades A; Lee J; Xu W; Chinchen S; Charakidis M; Thavaneswaran S; Hughes BGM; Underhill CR; Takhar HS; Harrup R; Nagrial A; Millward M; Desai J; Espinoza D; Lee CK; Solomon BJ; Simes J; Pavlakis N; Thomas D, 2024, '623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12', Annals of Oncology, 35, pp. S498 - S498, http://dx.doi.org/10.1016/j.annonc.2024.08.690

Kong BY; Lin FP-Y; Espinoza D; Thavaneswaran S; Meniawy T; Desai J; Harrup R; Selva-Nayagam S; Charakidis M; Cuff K; Sebastian L; Lee CK; Chinchen S; Thomas DM; Ballinger ML; Simes J; Goldstein D, 2024, '636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy', Annals of Oncology, 35, pp. S505 - S505, http://dx.doi.org/10.1016/j.annonc.2024.08.703

McNamee N; Lin F; Sim H-W; Napier C; Thomas D; Simes J; Thavaneswaran S, 2023, 'PATH-25. EXPLORING THE PROGNOSTIC IMPLICATIONS OF MOLECULAR ALTERATIONS IN ASTROCYTOMAS USING COMPREHENSIVE GENOMIC PROFILING (CGP)', Neuro-Oncology, 25, pp. v173 - v173, http://dx.doi.org/10.1093/neuonc/noad179.0655

Zeverijn LJ; Looze EJ; Thavaneswaran S; van Berge Henegouwen JM; Simes RJ; Hoes LR; Sjoquist KM; van der Wijngaart H; Sebastian L; Geurts BS; Lee CK; de Wit GF; Espinoza D; Roepman P; Lin FP; Jansen AML; de Leng WWJ; van der Noort V; Leek LVM; de Vos FYFL; van Herpen CML; Gelderblom H; Verheul HMW; Thomas DM; Voest EE, 2023, 'Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials', International Journal of Cancer, 153, pp. 1413 - 1422, http://dx.doi.org/10.1002/ijc.34649

Thavaneswaran S; Kansara M; Lin F; Espinoza D; Grady JP; Lee CK; Ballinger ML; Sebastian L; Corpuz T; Qiu MR; Mundra P; Bailey CG; Schmitz U; Simes J; Joshua AM; Thomas DM, 2023, 'A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations', British Journal of Cancer, 129, pp. 475 - 485, http://dx.doi.org/10.1038/s41416-023-02311-0

Zeverijn LJ; Looze E; Thavaneswaran S; van Berge Henegouwen JM; Simes J; Hoes LR; Geurts B; Sebastian L; Roepman P; Lin FP-Y; Jansen AML; de Leng WWJ; van der Noort V; Leek LVM; De Vos FYFL; Verheul HMW; Gelderblom H; Thomas DM; Voest EE; Sjoquist KM, 2023, 'Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.', Journal of Clinical Oncology, 41, pp. 3101 - 3101, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3101

Kansara M; Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 2594 - 2594, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2594

Thavaneswaran S; Lin FP-Y; Napier CE; Grady JP; Ballinger ML; Kansara M; Grimison PS; Pavlakis N; Wong MK; Sjoquist KM; Goldstein D; Chantrill LA; Simes J; Thomas DM, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.', Journal of Clinical Oncology, 41, pp. 4093 - 4093, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4093

Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Kansara M; Sebastian L; Kee D; Zaheed M; Millward M; Brown MP; Charakidis M; Craft PS; Grimison PS; Harrup RA; O'Byrne KJ; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.', Journal of Clinical Oncology, 41, pp. 1540 - 1540, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1540

Kee D; Lin FP-Y; Thavaneswaran S; Napier CE; Harrison ML; Beale PJ; Lynch J; Davis AJ; Ananda S; Lombard JM; Friedlander M; Kansara M; Sebastian L; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 5526 - 5526, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5526

Thavaneswaran S; Mersiades A; Lin FP-Y; Espinoza D; Grady JP; Lee CK; Desai J; Brown MP; Grimison PS; O'Byrne KJ; Harrup RA; Nagrial A; Sebastian L; Chinchen S; Kansara M; Craft PS; Millward M; Simes J; Joshua AM; Thomas DM, 2023, 'Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.', Journal of Clinical Oncology, 41, pp. 3127 - 3127, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3127

Kansara M; Bhardwaj N; Thavaneswaran S; Xu C; Lee JK; Chang LB; Madison RW; Lin F; Hsu E; Patel VK; Aleshin A; Oxnard GR; Simes J; Nimeiri H; Thomas DM, 2023, 'Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab', Molecular Oncology, 17, pp. 298 - 311, http://dx.doi.org/10.1002/1878-0261.13349

Yuile A; Satgunaseelan L; Alexander KL; Thavaneswaran S; Krasovitsky M; Buckland M; Lee M; Wei G; Kastelan M; Wong M; Wilson I; Bayly A; Varikat W; Sim H-W; Kong B; Lwin Z; Turner C; Back M; Miller S; Lee A; Wheeler H, 2022, 'CSIG-13. CLINICAL IMPACT OF CDKN2A/B DELETIONS IN IDH-MUTANT ASTROCYTOMAS', Neuro-Oncology, 24, pp. vii41 - vii41, http://dx.doi.org/10.1093/neuonc/noac209.162

Woodford R; Prather L; Helfer C; Davey L; Penas-Prado M; Armstrong T; Tucker K; Aldape K; Gilbert M; Clark C; Thavaneswaran S; Wang D; Mandel J; Kasherman L, 2022, 'Malignant melanocytic schwannian tumor and leptomeningeal disease: A case series with a focus on management', Journal of the Neurological Sciences, 438, http://dx.doi.org/10.1016/j.jns.2022.120291

Thavaneswaran S; Chan WY; Asghari R; Grady JP; Deegan M; Jansen VM; Thomas DM, 2022, 'Clinical Response to Seribantumab, an Anti-Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion', JCO PRECISION ONCOLOGY, 6, http://dx.doi.org/10.1200/PO.22.00263

Lin FP; Thavaneswaran S; Grady JP; Ballinger M; Kansara M; Oakes SR; Desai J; Lee CK; Simes J; Thomas DM, 2021, 'Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology', npj Precision Oncology, 5, pp. 58, http://dx.doi.org/10.1038/s41698-021-00194-z

Siu HWD; Tebbutt N; Chantrill L; Karapetis C; Steer C; Wilson K; Espinoza D; Bailey L; Yip S; Cuff J; Pavlakis N; Thavaneswaran S; Briscoe K; Srivastav R; Shannon J; Segelov E; Tie J; Caird S; Francesconi A; Price T; Wuttke M; Ladwa R; Sjoquist K; Burge M, 2021, 'MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)', BMC Cancer, 21, http://dx.doi.org/10.1186/s12885-021-08644-4

Thavaneswaran S; Ballinger M; Butow P; Meiser B; Goldstein D; Lin F; Napier C; Thomas D; Best M, 2021, 'The experiences and needs of australian medical oncologists in integrating comprehensive genomic profiling into clinical care: A nation-wide survey', Oncotarget, 12, pp. 2169 - 2176, http://dx.doi.org/10.18632/ONCOTARGET.28076

Joshua AM; Prawira A; Thavaneswaran S; Cosman R; Lee CK; Sjoquist KM; Simes J; Thomas DM; Espinoza D; Sebastian L; Ballinger ML; Hague W; Chinchen S; Collignon E; Kansara M; Palacios T; Grady J; Barker H; Thornton K, 2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', Journal of Clinical Oncology, 38, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3073

Lin F; Thavaneswaran S; Grady J; Ballinger M; Kansara M; Oakes S; Desai J; Lee CK; Simes J; Thomas D, 2020, 'Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology', , http://dx.doi.org/10.1101/2020.12.18.20248521

Thavaneswaran S; Rath E; Tucker K; Joshua AM; Hess D; Pinese M; Ballinger ML; Thomas DM, 2019, 'Author Correction: Therapeutic implications of germline genetic findings in cancer (Nature Reviews Clinical Oncology, (2019), 16, 6, (386-396), 10.1038/s41571-019-0179-3)', Nature Reviews Clinical Oncology, 16, pp. 397, http://dx.doi.org/10.1038/s41571-019-0212-6

Thavaneswaran S; Rath E; Tucker K; Joshua AM; Hess D; Pinese M; Ballinger ML; Thomas DM, 2019, 'Therapeutic implications of germline genetic findings in cancer', Nature Reviews Clinical Oncology, 16, pp. 386 - 396, http://dx.doi.org/10.1038/s41571-019-0179-3

Thavaneswaran S; Napier C; Goldstein D; Meiser B; Butow P; Thomas DM; Ballinger ML; Best M, 2019, 'Medical oncologists’ experience with returning molecular tumor profiling to patients.', Journal of Clinical Oncology, 37, pp. 10521 - 10521, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.10521

Shapiro JD; Thavaneswaran S; Underhill CR; Robledo KP; Karapetis CS; Day FL; Nott LM; Jefford M; Chantrill LA; Pavlakis N; Tebbutt NC; Price TJ; Khasraw M; Van Hazel GA; Waring PM; Tejpar S; Simes J; Gebski VJ; Desai J; Segelov E, 2018, 'Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study', Clinical Colorectal Cancer, 17, pp. 313 - 319, http://dx.doi.org/10.1016/j.clcc.2018.06.002

Thavaneswaran S; Sebastian L; Ballinger M; Best M; Hess D; Lee CK; Sjoquist KM; Hague WE; Butow PN; Simes RJ; Thomas D, 2018, 'Cancer Molecular Screening and Therapeutics (MoST): A framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers', Medical Journal of Australia, 209, pp. 354.e1 - 354.e6, http://dx.doi.org/10.5694/MJA18.00227

Thavaneswaran S; Kok PS; Price T, 2017, 'Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis', Expert Review of Anticancer Therapy, 17, pp. 965 - 979, http://dx.doi.org/10.1080/14737140.2017.1369881

Segelov E; Thavaneswaran S; Waring PM; Desai J; Robledo KP; Gebski VJ; Elez E; Nott LM; Karapetis CS; Lunke S; Chantrill LA; Pavlakis N; Khasraw M; Underhill C; Ciardiello F; Jefford M; Wasan H; Haydon A; Price TJ; Van Hazel G; Wilson K; Simes J; Shapiro JD, 2016, 'Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian gastro-intestinal trials group ICECREAM study', Journal of Clinical Oncology, 34, pp. 2258 - 2264, http://dx.doi.org/10.1200/JCO.2015.65.6843

Segelov E; Waring P; Desai J; Wilson K; Gebski V; Thavaneswaran S; Elez E; Underhill C; Pavlakis N; Chantrill L; Nott L; Jefford M; Khasraw M; Day F; Wasan H; Ciardiello F; Karapetis C; Joubert W; van Hazel G; Haydon A; Price T; Tejpar S; Tebbutt N, 2016, 'ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours', BMC Cancer, 16, http://dx.doi.org/10.1186/s12885-016-2389-8

Price T; Thavaneswaran S; Burge M; Segelov E; Haller D; Punt C; Arnold D; Karapetis C; Tebbutt N; Pavlakis N; Gibbs P; Shapiro J, 2016, 'Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015', Expert review of anticancer therapy, 16, pp. 557 - 571, http://dx.doi.org/10.1586/14737140.2016.1170594

Thavaneswaran S; Price TJ, 2016, 'Optimal therapy for resectable rectal cancer', Expert Review of Anticancer Therapy, 16, pp. 285 - 302, http://dx.doi.org/10.1586/14737140.2016.1130627

Thavaneswaran S; Shapiro J; Segelov E, 2016, 'Is there a role for epidermal growth factor receptor inhibition in the treatment of advanced esophagogastric tumours?', Translational Cancer Research, 5, pp. S1214 - S1221, http://dx.doi.org/10.21037/tcr.2016.11.29

Segelov E; Thavaneswaran S; Waring P; Desai J; Mann K; Elez E; Chantrill L; Pavlakis N; Nott L; Underhill C; Khasraw M; Wasan H; Ciardiello F; Jefford M; Joubert W; Haydon A; Karapetis C; Price T; Wilson K; Shapiro J, 2015, 'The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation', European journal of cancer, 51, pp. S726 - S726

Peterson TA; Bielawny T; Lacap P; Hardie R-A; Daniuk C; Mendoza L; Thavaneswaran S; Kariri T; Kimani J; Wachihi C; Kimani M; Ball TB; Plummer FA; Luo M, 2014, 'Diversity and Frequencies of HLA Class I and Class II Genes of an East African Population', Open Journal of Genetics, 04, pp. 99 - 124, http://dx.doi.org/10.4236/ojgen.2014.42013

Peterson TA; Kimani J; Wachihi C; Bielawny T; Mendoza L; Thavaneswaran S; Narayansingh MJ; Kariri T; Liang B; Ball TB; Ngugi EN; Plummer FA; Luo M, 2013, 'HLA class I associations with rates of HIV-1 seroconversion and disease progression in the Pumwani Sex Worker Cohort', Tissue Antigens, 81, pp. 93 - 107, http://dx.doi.org/10.1111/tan.12051

Peters HO; Mendoza MG; Capina RE; Luo M; Mao X; Gubbins M; Nagelkerke NJD; MacArthur I; Sheardown BB; Kimani J; Wachihi C; Thavaneswaran S; Plummer FA, 2008, 'An integrative bioinformatic approach for studying escape mutations in human immunodeficiency virus type 1 gag in the Pumwani sex worker cohort', Journal of Virology, 82, pp. 1980 - 1992, http://dx.doi.org/10.1128/JVI.02742-06

Conference Papers

Price TJ; Burge M; Chantrill L; Chua YJ; Horvath L; McLachlan S-A; Pavlakis N; Shapiro J; Thavaneswaran S; Tran B; Yip D; Tancock G, 2020, 'Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S1283 - S1283, presented at ESMO Asia Virtual Congress, ELECTR NETWORK, 20 November 2020 - 22 November 2020, http://dx.doi.org/10.1016/j.annonc.2020.10.127

Shapiro JD; Thavaneswaran S; Underhill C; Robledo KP; Karapetis CS; Day FL; Nott LM; Jefford M, 2017, 'Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.3572

Segelov E; Thavaneswaran S; Waring P; Desai J; Mann K; Elez E; Chantrill L; Pavlakis N; Nott L; Underhill C; Khasraw M; Wasan H; Ciardiello F; Jefford M; Joubert W; Haydon A; Karapetis C; Price T; Wilson K, 2015, 'The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.', in Eur J Cancer, Vienna, pp. S726 - S726, presented at European Cancer Congress, Vienna, 25 September 2015 - 29 September 2015

Conference Abstracts

Lin FP-Y; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2022, 'Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3073

Serie D; Pickering C; Rice R; Wong M; Huang H; Kansara M; Thavaneswaran S; Ballinger ML; Sebastian L; Thomas DM; Lindpaintner K, 2022, 'Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 11546 - 11546, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.11546

Serie D; Pickering C; Rice R; Wong M; Huang H; Kansara M; Thavaneswaran S; Ballinger ML; Sebastian L; Thomas DM; Lindpaintner K, 2022, 'Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680300387&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Thavaneswaran S; Ballinger ML; Grady J; Cowley M; Joshua A; Sebastian L; Collignon E; Silvestri A; Kansara M; Pinese M; Sjoquist KM; Hague W; Lee CK; Simes J; Thomas DM, 2019, 'The Cancer Molecular Screening and Therapeutics Program (MoST): Actionable mutation frequencies in a population with rare and less common cancers.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.3136

Thavaneswaran S; Sebastian L; Ballinger M; Cowley M; Grady J; Joshua A; Lee C; Sjoquist K; Hague W; Simes J; Thomas D, 2018, 'The cancer molecular screening and therapeutics program (MoST): A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies', in Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii147, http://dx.doi.org/10.1093/annonc/mdy279.434

Preprints

Thavaneswaran S; Lin FP; Kansara M; Grady JP; Espinoza D; Joshua AM; Grimison P; Craft P; Cosman R; Lee C; Harwood K; Chinchen S; Corpuz T; Ballinger M; Sebastian L; Simes J; Thomas D, 2022, A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers, http://dx.doi.org/10.1101/2022.06.30.22277092

Thavaneswaran S; Sebastian L; Kansara M; Ballinger M; Espinoza D; Lin F; Lee C; Sjoquist K; Grady J; Cowley M; Joshua A; Qiu M; Oakes S; Simes J; Thomas D, 2021, A Signal-seeking Phase Iia Trial of Palbociclib in Advanced Cancers With Cell Cycle Pathway Alterations – A Substudy of the Molecular Screening and Therapeutics (Most) Program, http://dx.doi.org/10.21203/rs.3.rs-254137/v1

Back to profile page